SVB Securities analyst Thomas Smith maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report) on May 12 and set a price target of $6.00. The company’s shares closed last Friday at $2.83.
Smith covers the Healthcare sector, focusing on stocks such as Immunic, Dice Therapeutics, and Celldex. According to TipRanks, Smith has an average return of 39.8% and a 49.54% success rate on recommended stocks.
Trevi Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.80, implying a 140.28% upside from current levels. In a report released on May 12, B.Riley Financial also reiterated a Buy rating on the stock with a $6.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $4.68 and a one-year low of $1.43. Currently, Trevi Therapeutics has an average volume of 88.21K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TRVI in relation to earlier this year. Most recently, in March 2023, Simon Farrell, the CCO of TRVI bought 18,750.00 shares for a total of $9,562.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
Read More on TRVI:
- Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
- TRVI Earnings this Week: How Will it Perform?
- Trevi Therapeutics initiated with a Buy at B. Riley
- Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)
- Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
